Seeking Alpha

  BioMarin Pharmaceutical Inc. - NASDAQ

11/26/2014, 9:25 AM ET
  • freefdawatchlist | Send Message 5 Nov 2012 Bearish call on $BMRN, 3k patient cannot generate 775 million in 2015. Its a sell with PT of 40.
      BMRN vs. ETF Alternatives
      Company Description
      Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and medical conditions. Its product portfolio is comprised of five product candidates Naglazyme, Kuvan, Aldurazyme, VIMIZIM and Firdapse.
      Sector: Healthcare
      Industry: Biotechnology
      Country: United States